Jeena Sikho Lifecare (NSE:JSLL) YoY EBITDA Growth: 76.04% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:JSLL Jeena Sikho Lifecare Ltd NSE:JSLL
92 GF Score
Price ₹559.35
GF Value ₹782.43
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Jeena Sikho Lifecare YoY EBITDA Growth?

Jeena Sikho Lifecare NSE:JSLL -2.53% 92 YoY EBITDA Growth is 76.04% as of Mar. 2026. GuruFocus rates NSE:JSLL with a GF Score™ of 92/100 and a GF Value™ of ₹782.43 (Modestly Undervalued). The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Jeena Sikho Lifecare's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 76.04%.

Jeena Sikho Lifecare's EBITDA per Share for the three months ended in Mar. 2026 was ₹6.52.

Jeena Sikho Lifecare YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Jeena Sikho Lifecare's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jeena Sikho Lifecare YoY EBITDA Growth Chart

Jeena Sikho Lifecare Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EBITDA Growth
Get a 7-Day Free Trial 10.02 149.17 103.76 48.44 142.85

Jeena Sikho Lifecare Quarterly Data
Mar19 Mar20 Mar21 Sep21 Mar22 Mar23 Mar24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 113.51 255.79 76.04
NSE:JSLL
92GF Score
Jeena Sikho Lifecare Ltd NSE:JSLL
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jeena Sikho Lifecare YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Jeena Sikho Lifecare's YoY EBITDA Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (A: Mar. 2026 )
=(EBITDA per Share (A: Mar. 2026 )-EBITDA per Share (A: Mar. 2025 ))/ | EBITDA per Share (A: Mar. 2025 ) |
=(28.734-11.832)/ | 11.832 |
=142.85 %

Jeena Sikho Lifecare's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(6.524-3.706)/ | 3.706 |
=76.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 76.04% mean?
Jeena Sikho Lifecare (NSE:JSLL) has a YoY EBITDA Growth of 76.04% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Jeena Sikho Lifecare and its competitors.
Is Jeena Sikho Lifecare's YoY EBITDA Growth too high?
Jeena Sikho Lifecare's current YoY EBITDA Growth is 76.04%. Overall, Jeena Sikho Lifecare has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jeena Sikho Lifecare's YoY EBITDA Growth compare to HCA and THC?
Jeena Sikho Lifecare's YoY EBITDA Growth of 76.04% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Jeena Sikho Lifecare and its competitors. Jeena Sikho Lifecare's current YoY EBITDA Growth is 76.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jeena Sikho Lifecare stock overvalued right now?
Based on GuruFocus' analysis, Jeena Sikho Lifecare (NSE:JSLL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹782.43, compared to a current price of ₹559.35 — trading 28.5% below its estimated fair value. The current YoY EBITDA Growth is 76.04%. Jeena Sikho Lifecare's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Jeena Sikho Lifecare (NSE:JSLL), the current YoY EBITDA Growth is 76.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jeena Sikho Lifecare (NSE:JSLL) Overvalued in 2026?

Based on GuruFocus' analysis, Jeena Sikho Lifecare stock appears to be undervalued. The current stock price of ₹559.35 is trading 28.5% below its estimated GF Value™ of ₹782.43. GuruFocus considers Jeena Sikho Lifecare to be Modestly Undervalued.

Key valuation signals for NSE:JSLL:

  • YoY EBITDA Growth: 76.04%
  • GF Value™: ₹782.43 vs. price of ₹559.35 (28.5% below fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the NSE:JSLL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jeena Sikho Lifecare Business Description

Other Exchanges 544476:India
Address Kalgidhar Enclave, SCO 11 First Floor, Mohali, Zirakpur, PB, IND, 140604
Jeena Sikho Lifecare Ltd provides Ayurvedic healthcare products and services. The company operates only in one business segment which is Trading of Ayurvedic Medicines and providing Ayurvedic therapies. The company engages in conducting health check-up camps, and free yoga sessions to make people aware of health problems. It offers a wide range of Ayurvedic products such as Shuddhi 32 Herbs Tea, Shuddhi Addiction Free Kit, Shuddhi BP Package, Shuddhi Diabetes Care Package, and Shuddhi Divya Sanjeevani-Anti-Viral Package.
92GF Score

Get the complete analysis for NSE:JSLL

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹559.35
Price
₹782.43
GF Value